Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11402843 | 0.89 | MAPT (0.63) | CYP19A1ALDH1A1HPGDRAB9AGAA | |
| SCHEMBL6391622 | 0.85 | ALDH1A1 (0.58) | CYP19A1ALDH1A1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL11453702 | 0.84 | MAPT (0.58) | CYP19A1ALDH1A1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL30599548 | 0.84 | MAPT (0.66) | ALDH1A1SMN1; SMN2HPGDRAB9AGAA | |
| SCHEMBL1188378 | 0.84 | MAPT (0.66) | ALDH1A1SMN1; SMN2HPGDRAB9AGAA | |
| SCHEMBL11064084 | 0.82 | MAPT (0.68) | CYP19A1ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL11595669 | 0.82 | ALDH1A1 (0.57) | CYP19A1ALDH1A1SMN1; SMN2HPGDGAA | |
| SCHEMBL11065326 | 0.82 | MAPT (0.55) | CYP19A1ALDH1A1HPGDRAB9AGAA | |
| SCHEMBL11612418 | 0.82 | GPR35 (0.61) | CYP19A1ALDH1A1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL11651728 | 0.82 | HPGD (0.61) | CYP19A1ALDH1A1SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| US-4483707-A | PLANT SAFTENING AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CYP19A1 618/4885ALDH1A1 530/4885SMN1; SMN2 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.